Liu, Joyce F <br/><br/>
Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer.  [electronic resource] 

 -  Gynecologic oncology  07 2019 
 - 95-101 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1095-6859 
<br/><br/><label>Standard No.: </label>10.1016/j.ygyno.2019.05.003  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Diamines--administration & dosage<br/>Female<br/>Humans<br/>Kaplan-Meier Estimate<br/>MAP Kinase Kinase Kinases--antagonists & inhibitors<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Phosphoinositide-3 Kinase Inhibitors<br/>Progression-Free Survival<br/>Proto-Oncogene Proteins c-akt--antagonists & inhibitors<br/>Pyrazoles--administration & dosage<br/>Pyridones--administration & dosage<br/>Pyrimidinones--administration & dosage<br/>Signal Transduction--drug effects<br/>Uterine Cervical Neoplasms--drug therapy